Easywell Biomedicals, Inc. (TPEX:1799)

Market Cap	8.26B
Revenue (ttm)	483.81M
Net Income (ttm)	-120.87M
Shares Out	121.79M
EPS (ttm)	-1.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,112,054
Average Volume	304,615
Open	72.00
Previous Close	71.00
Day's Range	67.50 - 72.30
52-Week Range	51.50 - 233.00
Beta	0.72
RSI	66.44
Earnings Date	Mar 28, 2025

About Easywell Biomedicals

Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in America. It operates through Drug Development and Other segments. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 1799

Financial Performance

In 2023, Easywell Biomedicals's revenue was 271.63 million, an increase of 51.83% compared to the previous year's 178.90 million. Losses were -144.82 million, -10.05% less than in 2022.